Skip to main content
OpenTrials
Completed

NCT Number: NCT06840964

Effect of Omega 3 in Hypertensive Patients

This study aims to evaluate the impact of omega-3 (O3) supplementation in participants with high blood pressure and elevated triglycerides, focusing on cardiovascular risk factors. The research is particularly relevant, as O3 has been previously validated for its effects on abnormal lipid levels. The primary and secondary objectives aim to explore the effects of O3, as well as its potential therapeutic benefits in preventing cardiovascular diseases.

The main goal of this research is to investigate how O3 supplementation influences several key cardiovascular risk markers and overall vascular health. Specifically, the study will assess and analyze changes in cholesterol levels, triglycerides, uric acid, and blood glucose levels. Since inflammation plays a major role in heart disease, the study will examine how O3 affects inflammatory markers, including ferritin, high-sensitivity C-reactive protein (hsPCR), and the neutrophil-to-leukocyte ratio. These indicators help determine the level of systemic inflammation in the body. The study also aims to measure whether O3 supplementation improves vascular elasticity.

Apart from the primary cardiovascular effects, the study also aims to determine the tolerance levels of participants receiving O3 supplementation based on their cardiovascular profiles.

The study is based on the hypothesis that taking 2 grams of O3 daily for 12 weeks will lead to a significant reduction in triglyceride levels, lower inflammation markers, improved metabolic risk factors, and enhanced arterial elasticity, which can prevent or slow the progression of cardiovascular diseases. This hypothesis is supported by growing scientific evidence that suggests O3 fatty acids, particularly long-chain polyunsaturated fatty acids (DHA and EPA), have strong cardioprotective properties.

This is a clinical study that is planned in a prospective, interventional, randomized, placebo-controlled, and double-blind format. This means that participants will be randomly assigned to either the treatment group or the placebo group, and neither the participants nor the researchers will know who is receiving the actual treatment until the study ends.

This study is a pilot study, meaning it is a small-scale preliminary study designed to test the hypothesis before conducting a larger trial.

A total of 100 participants will be recruited. Participants will be randomly assigned into two groups: O3 group, receives omega-3 (O3) treatment; and control group, receives a placebo. The assignment will be 1:1 randomization, meaning each participant has an equal (50%) chance of receiving either the treatment or the placebo. The number of participants was chosen based on estimates that a 10% reduction in blood pressure measurements (mean arterial, brachial systolic, brachial diastolic, or central systolic) would be a meaningful outcome.

The duration of omega-3 intervention is based on previous research.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hypertension Cardiovascular Diseases Dyslipidemia Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases Vascular Diseases

Age range

21 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Santa Maria de la Salud

San Isidro, Buenos Aires, 1642, Argentina

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signature of informed consent to participate. Without situations that potentially cause their departure from the country or the possibilities of follow-up during the study.

Diagnosis of hypertriglyceridemia defined as mild 150-199 mg/ moderate 200-499 mg and severe more than 500 mg.

Diagnosis of controlled arterial hypertension (BP ≤140/90 mm Hg) with stable pharmacological treatment (definitions of the Argentine Consensus on HTA, 2018).

Women of childbearing age will be included only if they are under contraceptive treatment, adopted prior to the invitation to participate in the study (hormonal contraceptives (oral, injectable, implantable, etc., intrauterine devices).

Exclusion criteria

  • Hypersensitivity to the active ingredient, or to soy, or allergy to fish. Liver failure. Pregnancy and breastfeeding. Active anticoagulant treatment. Women of childbearing age who do not use contraceptive methods prior to the invitation to the study.

Treatment and study plan

omega 3 ethyl esters at 90%

Dietary Supplement

2 grams/day of omega 3 capsules will be administered orally, for 12 weeks

Placebo

Dietary Supplement

Mygliol 812

Primary outcomes

  1. Mean change in office systolic blood pressure from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Mean change in office Systolic blood pressure from baseline in Millimeter Mercury, it measures average changes in office systolic blood pressure.

    Blood pressure is assessed using standardized methods while the participant is seated and resting. The measurement is taken using a validated electronic BP monitor.

  2. Mean change in office diastolic blood pressure from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Mean change in office Diastolic blood pressure from baseline in Millimeter Mercury, it measures average changes in office diastolic blood pressure. Blood pressure is assessed using standardized methods while the participant is seated and resting. The measurement is taken using a validated electronic BP monitor.

  3. Mean change in 24h and Daytime Ambulatory Systolic Arterial Blood Pressure from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Mean change in 24h and Daytime Ambulatory Systolic blood pressure from baseline in Millimeter Mercury, it measures average changes in systolic blood pressure. Blood pressure is assessed using standardized methods for 24 hour ambulatory measurement using a validated BP device monitor.

  4. Mean change in 24h and Daytime Ambulatory Diastolic Arterial Blood Pressure from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Mean change in 24h and Daytime Ambulatory Diastolic blood pressure from baseline in Millimeter Mercury, it measures average changes in diastolic blood pressure. Blood pressure is assessed using standardized methods for 24 hour ambulatory measurement using a validated BP device monitor.

  5. Mean change in resting pulse wave velocity from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Measurement of pulse wave velocity (PWV) in meters per second. The calibrated and validated Mobil-O-Graph® portable monitor (IEM GmbH, Stolberg, Germany) will be used. This module is connected to a computer to record the brachial pulse wave. It performs pulse wave analysis based on the oscillometric method. The arterial pulsation generates pressure oscillations, which are transmitted to the blood pressure cuff and measured by the transducer to be interpreted by a specific software, recording the pulse wave of the brachial artery and deriving a pulse wave from the aortic arch.

    All measurements will be performed on the left arm of the participant, at rest. Subjects will be instructed to be with empty bladder, not to drink coffee 60 minutes before gauging and alcoholic beverage in the last 24 hours.

  6. Mean change in total cholesterol from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Mean change in cholesterol in Milligram/deciliter from baseline, it measures average changes in cholesterol.

  7. Mean change in high density lipoprotein from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Mean change in high density lipoprotein (HDL) in Milligram/deciliter from baseline, it measures average changes in (HDL) cholesterol.

  8. Mean change in triglycerides from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Mean change in triglycerides in Milligram/deciliter from baseline, it measures average changes in plasma triglycerides.

  9. Mean change in fasting blood sugar from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Mean change in fasting blood sugar in Milligram/deciliter from baseline, it measures average changes in fasting blood sugar.

  10. Mean change in high sensitive C reactive protein from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Mean change in high sensitive C reactive protein (Hs-CRP) in Milligram/liter, it measures average changes in high sensitive C reactive protein (Hs-CRP).

  11. Mean change in serum aspartate aminotransferase/serum glutamic-oxaloacetic transaminase from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Serum aspartate aminotransferase/serum glutamic-oxaloacetic transaminase (AST/SGOT) in units per liter (U/L).

  12. Mean change in serum alanine transaminase/Serum Glutamic Pyruvic Transaminase from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Serum alanine transaminase/Serum Glutamic Pyruvic Transaminase (ALT/SGPT) in units per liter (U/L).

  13. Mean change in fasting plasma insulin from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Fasting plasma insulin after fasting for 8-12 hours. Results are reported in micro International Units per milliliter (uIU/mL)

  14. Mean change in serum ferritin from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    Serum ferritin is measured in nanograms per milliliter (ng/mL)

  15. Mean change in neutrophil-to-lymphocyte ratio from baseline

    Time frame: From enrollment to the end of treatment at 12 weeks

    The neutrophil-to-lymphocyte ratio (NLR) is a measurement of the number of neutrophils compared to the number of lymphocytes in a blood sample. It's calculated by dividing the absolute neutrophil count by the absolute lymphocyte count. An automated cell counter with mixed technologies performs the calculation.

Secondary outcomes

  1. Tolerability and safety

    Time frame: From enrollment to the end of treatment at 12 weeks

    Presence or not, described by participants, of any of the known side effects , such as belching, indigestion, and diarrhea; or symptoms such as rash, itching, swelling, severe dizziness, or trouble breathing

Sponsors and collaborators

Lead sponsor

Santa Maria de la Salud, Argentina

Other

Collaborators

  • Gador S.A.

Registry information

Official study title

Analysis of the Effect of Acidified Omega 3 Esters (DHA+EPA) in Hypertensive Patients With Increased Triglycerides

Acronym: OMECARDIO

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Feb 21, 2025
Registry last updated
Feb 21, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.